Oculis Holding AG (OCS)
NASDAQ: OCS · Real-Time Price · USD
9.27
-0.14 (-1.49%)
At close: Sep 25, 2026, 4:00 PM EDT
9.25
-0.02 (-0.22%)
After-hours: Sep 25, 2026, 7:30 PM EDT
Oculis Holding AG Revenue
Oculis Holding AG had revenue of 310.00K CHF in the quarter ending June 30, 2026, with 18.77% growth. This brings the company's revenue in the last twelve months to 1.17M, up 53.33% year-over-year. In the year 2025, Oculis Holding AG had annual revenue of 1.20M with 74.78% growth.
Revenue (ttm)
1.17M CHF
Revenue Growth
+53.33%
P/S Ratio
394.19
Revenue / Employee
19,550 CHF
Employees
60
Market Cap
572.26M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.20M | 513.00K | 74.78% |
| Dec 31, 2024 | 686.00K | -197.00K | -22.31% |
| Dec 31, 2023 | 883.00K | -29.00K | -3.18% |
| Dec 31, 2022 | 912.00K | -48.00K | -5.00% |
| Dec 31, 2021 | 960.00K | -33.00K | -3.32% |
| Dec 31, 2020 | 993.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 462.25M |
| Phathom Pharmaceuticals | 239.66M |
| Valneva SE | 163.30M |
| CytomX Therapeutics | 18.30M |
| Crescent Biopharma | 11.88M |
| Allogene Therapeutics | 4.64M |
| Prime Medicine | 4.07M |
| Altimmune | 31.00K |
OCS News
- 9 days ago - Oculis price target raised to $39 from $26 at H.C. Wainwright - TheFly
- 10 days ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewsWire
- 12 days ago - Oculis Holding AG Transcript: 2026 Global Healthcare Conference - Transcripts
- 13 days ago - Oculis Holding AG Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 4 weeks ago - First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis - GlobeNewsWire
- 6 weeks ago - Oculis price target lowered to $20 from $23 at JPMorgan - TheFly
- 6 weeks ago - Oculis price target lowered to $32 from $35 at BofA - TheFly
- 6 weeks ago - Oculis to acquire development, commercial rights to Privosegtor from Accure - TheFly